Tag: agency

Novo Nordisk's Wegovy® pill has been approved in the UK as an adjunct to a reduced-calorie diet and increased physical activity for adults

A national demonstration project developed by State Grid Jibei Zhangjiakou Wind-Solar-Storage New Energy Co., Ltd., to strengthen grid stability.

SALT LAKE CITY, June 11, 2026 /PRNewswire/ -- "FatPipe, Inc. (NASDAQ: FATN) ("FatPipe" or the "Company"), today announced the general availability of FatPipe SATBoost,...

Cosmos Health secures additional 180-day Nasdaq extension to regain compliance.

60 Degrees Pharma licensed FSU technology for Australian Chestnut Extract production and plans FDA discussions before refiling its NDIN.

Industry veterans bring deep expertise in advanced reactor deployment, nuclear operations and regulatory licensing to support company’s U.S. growth

Industry veterans bring deep expertise in advanced reactor deployment, nuclear operations and regulatory licensing to support company’s U.S. growth

VANCOUVER, BC, June 11, 2026 /CNW/ - FPX Nickel Corp. (TSXV: FPX) (OTCQX: FPOCF) ("FPX" or the "Company") acknowledges that, as previously anticipated, the Impact Assessment...

CDP to become two separate organisations – CDP, a commercial entity backed by Permira, and CDP Foundation, a non-profit, charitable organisation focused on pioneering...

Patients in the IMAAVY 30 mg/kg treatment groupa achieved statistically significant durable hemoglobin responseb, with mean hemoglobin improvement of at least 1 g/dL as...

Almost half of UK consumers want a Summer Black Friday Promotion, new Independent research shows*Black Friday offers, but hotter: Joybuy's Summer Black Friday offers...

DURHAM, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the pricing of an underwritten public offering of 47,619,048 shares of its common stock at a public offering price of $1.05 per share. The aggregate gross proceeds from this offering are expected to be $50 million, before deducting underwriting discounts and commissions and other offering expenses payable by Humacyte. The closing of the offering is expected to occur on or about June 12, 2026, subject to the satisfaction of customary closing conditions. In addition, Humacyte has granted the underwriters an option for a period of 30 days to purchase up to an additional 7,142,857 shares of Humacyte’s common stock at the public offering price, less underwriting discounts and commissions. All of the shares of common stock are being sold by Humacyte.

NEW TAIPEI CITY, June 10, 2026 /PRNewswire/ -- GlycoNex, Inc. (4168, hereinafter referred to as GNX), today announced that the Phase III clinical trial...